<DOC>
	<DOCNO>NCT00527449</DOCNO>
	<brief_summary>The purpose study optimize result neoadjuvant chemotherapy local advance primary breast cancer . Therefore patient become first 3 cycle Epirubicin/Docetaxel follow 3x Carboplatin/Docetaxel .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Primary Breast Cancer With Epirubicin/Docetaxel Carboplatin/Docetaxel</brief_title>
	<detailed_description>Most woman diagnose breast cancer situation operation possible . Using neoadjuvant therapy rate breast-conserving surgery extend tumor cell proliferation may inhibit . Further neoadjuvant chemotherapy in-vivo-activity-test use drug . Epirubicin , Docetaxel Carboplatin show antineoplastic activity solid cancer alone combination . Using two different combination three drug , first 3 cycle Epirubicin/Docetaxel change Carboplatin/Docetaxel 3 cycle assume result therapy improve . Main criterion determination pCR , second criterion rate breast-conserving surgery , tumor response therapy-dependent toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>histologically assure breast cancer age &gt; = 18 year bone marrow function : neutrophil &gt; = 1.5x109/l , platelet &gt; = 100x109/l , hemoglobin &gt; =6.2 mmol/l sufficient renal liver function ECOG 02 write informed consent pregnant nursing woman distant metastasis T2Tumour &lt; 3cm G1 exist motoric sensoric neurotoxicity &gt; Grade 2 know hypersensitivity Epirubicin anthracycline Carboplatin platin derivative Docetaxel substance prepare solution</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>